Plain-English translation of NCT06714630 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →The PROSECCA Study is using artificial intelligence to analyze the medical records of up to 15,000 prostate cancer patients in Scotland who have received radiotherapy. Researchers are looking for patterns in patients' health histories that might predict who will have difficulty tolerating radiation or experience more side effects from treatment. By identifying these patterns earlier, doctors may be able to personalize treatment plans and help future prostate cancer patients receive safer, more effective care.
Currently, doctors cannot easily predict which prostate cancer patients will struggle with radiotherapy side effects before treatment begins. This study aims to use artificial intelligence to spot warning signs in patients' medical histories that could help doctors adjust treatment plans in advance and ultimately improve outcomes for prostate cancer patients.
You likely qualify if…
You likely don't qualify if…
This is not a traditional clinical trial where you would visit a clinic or take new medication. Instead, researchers will use your existing medical records and healthcare data that are already stored in Scottish health systems. Your participation involves allowing researchers to link your radiotherapy records with your broader health history so they can analyze patterns using artificial intelligence. No new appointments, tests, or treatments are required from you.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United Kingdom